Therapeutic Efficacy of an Injectable Formulation of Purinostat Mesylate in SU-DHL-6 Tumour Model

Overview

Journal Ann Med

Publisher Informa Healthcare

Specialty General Medicine

Date 2022 Mar 4

PMID 35243950

Authors

Zejiang Zhu

Jiaolin Wen

Yaohui Xu

Heying Pei

Dan Li

Minghai Tang

Peng Bai

Jun He

Zhuang Yang

Lijuan Chen

Affiliations

Soon will be listed here.

Abstract

Previous studies have proven that Purinostat Mesylate (PM) is a new HDAC inhibitor and exhibits significant antitumor efficacy. However, the clinical application of PM was greatly limited by its poor solubility in water and low bioavailability.To increase the solubility of PM through pharmaceutical research, and prepare it into an injection that meets the needs of intravenous use to promote its clinical application.The prepared PM/HP-β-CD inclusion complex was studied by computer simulation, fourier transform infrared spectroscopy (FT-IR), nuclear magnetic resonance (1H-NMR spectroscopy), and scanning electron microscopy (SEM). Then, the antitumor effects of PM/HP-β-CD inclusion complex were studied by in vitro cytotoxicity assay, apoptosis assay, pharmacokinetic study and in vivo antitumor assay.Phase Solubility Analysis revealed that PM and HP-β-CD were compatible and the solubility of PM increased almost 220 times, to 2.02 mg/mL. The interaction mechanism studies revealed that PM could be embedded into the cavity of HP-β-CD through the side of the aminobenzene ring. Cell viability and apoptosis assays showed that PM/HP-β-CD complex maintained the good anti-cancer activity of PM, and PM/HP-β-CD complex has a better anti-tumor effect and lower toxicity than LBH589 and Hyper-CVAD/RTX in vivo. All the results suggest that HP-β-CD can solve the problem of PM administration and provide a way for clinical application of PM. In this study, an injectable formulation of PM in HP-β-CD (10% w/v) was prepared to improve its water solubility. Our research provides a way for clinical administration of PM, which has been under phase I clinical trial for the treatment of relapsed or refractory B-cell-related hematologic malignancies in China and the USA.KEY MESSAGESWe developed a preparation of Purinostat Mesylate that can be administered intravenously, reducing the toxicity associated with oral administration.This preparation has an outstanding therapeutic effect on SU-DHL-6 xenograft tumour, indicating its clinical value, which has been under phase I clinical trial for the treatment of relapsed or refractory B-cell-related haematologic malignancies in China and the USA.

Citing Articles

Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.

Zhao A, Zhou H, Yang J, Li M, Niu T Signal Transduct Target Ther. 2023; 8(1):71.

PMID: 36797244 PMC: 9935927. DOI: 10.1038/s41392-023-01342-6.

HDAC I/IIb selective inhibitor Purinostat Mesylate combined with GLS1 inhibition effectively eliminates CML stem cells.

Qiu Q, Yang L, Feng Y, Zhu Z, Li N, Zheng L Bioact Mater. 2022; 21:483-498.

PMID: 36185739 PMC: 9486186. DOI: 10.1016/j.bioactmat.2022.08.006.

References

Furutani E, Shimamura A . Germline Genetic Predisposition to Hematologic Malignancy. J Clin Oncol. 2017; 35(9):1018-1028. PMC: 5559882. DOI: 10.1200/JCO.2016.70.8644. View

Fitzmaurice C, Allen C, Barber R, Barregard L, Bhutta Z, Brenner H . Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2016; 3(4):524-548. PMC: 6103527. DOI: 10.1001/jamaoncol.2016.5688. View

Qiu N, Cheng X, Wang G, Wang W, Wen J, Zhang Y . Inclusion complex of barbigerone with hydroxypropyl-β-cyclodextrin: preparation and in vitro evaluation. Carbohydr Polym. 2013; 101:623-30. DOI: 10.1016/j.carbpol.2013.09.035. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

Chen Y, Wang X, Xiang W, He L, Tang M, Wang F . Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities. J Med Chem. 2016; 59(11):5488-504. DOI: 10.1021/acs.jmedchem.6b00579. View

Aukema S, Siebert R, Schuuring E, van Imhoff G, Kluin-Nelemans H, Boerma E . Double-hit B-cell lymphomas. Blood. 2010; 117(8):2319-31. DOI: 10.1182/blood-2010-09-297879. View

Buuh Z, Lyu Z, Wang R . Interrogating the Roles of Post-Translational Modifications of Non-Histone Proteins. J Med Chem. 2017; 61(8):3239-3252. DOI: 10.1021/acs.jmedchem.6b01817. View

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

Huang P, Hu S, Yen F, Tseng C . Improvement of Skin Penetration, Antipollutant Activity and Skin Hydration of 7,3',4'-Trihydroxyisoflavone Cyclodextrin Inclusion Complex. Pharmaceutics. 2019; 11(8). PMC: 6723501. DOI: 10.3390/pharmaceutics11080399. View

10.

Mohammad R, Al-Katib A, Aboukameel A, Doerge D, Sarkar F, Kucuk O . Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. Mol Cancer Ther. 2004; 2(12):1361-8. View

11.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

12.

Brewster M, Loftsson T . Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev. 2007; 59(7):645-66. DOI: 10.1016/j.addr.2007.05.012. View

13.

Toner L, Vrhovac R, Smith E, Gardner J, Heaney M, Gonen M . The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma. Clin Cancer Res. 2006; 12(3 Pt 1):924-32. DOI: 10.1158/1078-0432.CCR-05-0331. View

14.

Ma S, Chen W, Yang X, Zhang N, Wang S, Liu L . Alpinetin/hydroxypropyl-β-cyclodextrin host-guest system: preparation, characterization, inclusion mode, solubilization and stability. J Pharm Biomed Anal. 2012; 67-68:193-200. DOI: 10.1016/j.jpba.2012.04.038. View

15.

Yang L, Qiu Q, Tang M, Wang F, Yi Y, Yi D . Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of -Induced B-Cell Acute Lymphoblastic Leukemia. Clin Cancer Res. 2019; 25(24):7527-7539. DOI: 10.1158/1078-0432.CCR-19-0516. View

16.

Narita T, Weinert B, Choudhary C . Functions and mechanisms of non-histone protein acetylation. Nat Rev Mol Cell Biol. 2018; 20(3):156-174. DOI: 10.1038/s41580-018-0081-3. View

17.

Esteve-Arenys A, Valero J, Chamorro-Jorganes A, Gonzalez D, Rodriguez V, Dlouhy I . The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma. Oncogene. 2018; 37(14):1830-1844. DOI: 10.1038/s41388-017-0111-1. View

18.

Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin D, Pineros M . Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2018; 144(8):1941-1953. DOI: 10.1002/ijc.31937. View

19.

Parkin D, Bray F, Ferlay J, Pisani P . Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74-108. DOI: 10.3322/canjclin.55.2.74. View

20.

Gould S, Scott R . 2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review. Food Chem Toxicol. 2005; 43(10):1451-9. DOI: 10.1016/j.fct.2005.03.007. View